Role of Hypoxia-Induced Brain Derived Neurotrophic Factor in Human Pulmonary Artery Smooth Muscle

William Hartman1*, Martin Helan3,4, Dan Smelter1, Venkatachalem Sathish1,2, Michael Thompson1, Christina M. Pabelick1,2, Bruce Johnson5,2, Y. S. Prakash1,2

1 Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, 55905, United States of America, 2 Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905, United States of America, 3 International Clinical Research Center, Department of Cardiovascular Diseases, St. Anne’s University Hospital, Brno, Czech Republic, 4 Department of Anesthesiology and Intensive Care, St. Anne’s University Hospital, Masaryk University, Brno, Czech Republic, 5 Department of Internal Medicine, Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, 55905, United States of America

* hartman.william@mayo.edu

Abstract

Background

Hypoxia effects on pulmonary artery structure and function are key to diseases such as pulmonary hypertension. Recent studies suggest that growth factors called neurotrophins, particularly brain-derived neurotrophic factor (BDNF), can influence lung structure and function, and their role in the pulmonary artery warrants further investigation. In this study, we examined the effect of hypoxia on BDNF in humans, and the influence of hypoxia-enhanced BDNF expression and signaling in human pulmonary artery smooth muscle cells (PASMCs).

Methods and Results

48h of 1% hypoxia enhanced BDNF and TrkB expression, as well as release of BDNF. In arteries of patients with pulmonary hypertension, BDNF expression and release was higher at baseline. In isolated PASMCs, hypoxia-induced BDNF increased intracellular Ca²⁺ responses to serotonin: an effect altered by HIF1α inhibition or by neutralization of extracellular BDNF via chimeric TrkB-Fc. Enhanced BDNF/TrkB signaling increased PASMC survival and proliferation, and decreased apoptosis following hypoxia.

Conclusions

Enhanced expression and signaling of the BDNF-TrkB system in PASMCs is a potential mechanism by which hypoxia can promote changes in pulmonary artery structure and function. Accordingly, the BDNF-TrkB system could be a key player in the pathogenesis of hypoxia-induced pulmonary vascular diseases, and thus a potential target for therapy.
Introduction

Diseases such as pulmonary hypertension (PH) are characterized by enhanced pulmonary artery (PA) constriction as well as arterial wall remodeling, the latter involving increased PA smooth muscle cell (PASMC) proliferation and survival but decreased apoptosis.[1,2,3] Accordingly, understanding mechanisms that alter PA remodeling and contractility is important.[1,4,5] Chronic hypoxia is a well-recognized contributor to PH[6,7] enhancing PASMC intracellular Ca2+ ([Ca2+]i) regulation and contractility[8,9] as well as cellular proliferation.[10,11] Therefore, the mechanisms by which hypoxia affects the PA become particularly relevant.

There is substantial interest in locally-produced growth factors (e.g. vascular endothelial growth factor) released within the PA in response to hypoxia with autocrine/paracrine effects on PASMCs.[12,13] In this regard, the family of neurotrophins, well-known in the nervous system,[14,15] may be relevant to the PA. Neurotrophins act via both high-affinity tropomyosin related kinase (Trk) and low-affinity p75NTR receptors, activating pathways including phospholipase C, PI3 kinase, mitogen activated protein kinases (MAPK), and NFκB.[15,16] They can genomically and non-genomically alter [Ca2+]i[17] as well as cell proliferation, survival and migration.[15,18] There is now increasing evidence (including our own) that neurotrophins such as brain-derived neurotrophic factor (BDNF) and their receptors (TrkB) are expressed and functional within the airways and pulmonary vasculature.[19,20,21,22] For example, Kwapiszewska et al. reported that BDNF/TrkB interactions can augment PASMC cell proliferation in idiopathic pulmonary hypertension. [23] In pulmonary endothelium and in airways, BDNF enhances [Ca2+]i[19], and NO generation[22] and in airway smooth muscle, BDNF promotes [Ca2+]i, responses[24] and cellular proliferation.[25] Further, hypoxia enhances PA endothelial cell (PAEC) synthesis and secretion of BDNF.[26,27]Given this, there is merit in further investigating the functional consequences of BDNF/TrkB expression in the PA, particularly following hypoxia exposure, and to determine how BDNF may interact with hypoxia signaling mechanisms to alter the structure and function of the PA.

In the brain, hypoxia increases BDNF expression,[28,29] and BDNF may modulate neuronal cell survival.[30] Similarly, BDNF has been shown to play a role in cardiac myocyte survival following infarction.[31] Furthermore, in neuroblastoma cell lines[32] as well as rat airway cell lines,[33] TrkB expression is mediated, in part, by exposure to low oxygen tensions. In this regard, the promoter of human NTRK2 gene, which encodes TrkB, contains at least three hypoxia-inducible factor (HIF) response elements.[34] Based on this information, we hypothesized that hypoxia enhances the BDNF-TrkB system in PASMCs, allowing BDNF to mediate and modulate the effects of hypoxia on arterial contractility and remodeling. The relevance of our study lies in demonstrating the potential importance of how BDNF/TrkB interactions could contribute to hypoxia effects in the PA, setting the stage for exploration of hypoxia-exacerbated diseases such as PH.

Materials and Methods

1. Human PA and PASMCs

Under a Mayo Institutional Board-approved protocol, PASMCs were isolated from 3–4 mm diameter branch PAs of lung samples incidental to patient thoracic surgery at Mayo Clinic-Rochester. Samples were from lobectomies or pneumonectomies for focal non-infectious indications such as localized tumors, and were classified as being non-PH or PH based on clinical data. The limited PH data set was entirely mild-moderate, where mean PAP clinically estimated by transthoracic or transesophageal echocardiography ranged from 25 mmHg (mild) to
48 mmHg (moderate), given high anesthesia risk for non-transplant surgeries in severe PH. Samples were limited to areas distant from the focal pathologies as identified by the pathologist and verified under gross microscopy. Since the samples and clinical data were de-identified, the protocol was considered minimal risk Human Subjects Research.

Samples were transported rapidly in ice-cold Hank’s Balanced Salt Solution (HBSS). The PA segment was partitioned for testing of endothelium-intact PA, and for analysis of endothelium- and adventitia-denuded PA smooth muscle. The latter was used as tissue or for isolation of PASMCs, which involved mincing and growth of explants in DMEM with 10% FBS/1% ABAM. Tissue explants were maintained for 5–7 days at 37°C in 95% air/5% CO2 after which the source tissue was removed and cells plated in 60mm dishes (Western analysis), 8 well Lab-tek culture chambers or 96 well plates (imaging and proliferation assays). Prior to experimentation, cells were serum-deprived for 24h, and all cells were used between passages 1 and 4 to ensure maintenance of PASMC phenotype, verified by markers such as smooth muscle actin and myosin, and transgelin (SM22), but absence of fibroblast specific protein.

2. PA and PASMC Exposures

For hypoxia, intact PA or isolated PASMCs were exposed to 1% O2 for 48h in a hypoxia chamber (Biospherix C-chamber). The chamber was flushed 3 times for 10 min each with high flow 1% O2 prior to use. For BDNF exposure, intact PA or isolated PASMCs were incubated for 24 or 48 h (see protocols) at 37°C in regular growth media (vehicle control) or 100 pM recombinant human BDNF (#248BD, R&D Systems, Minneapolis, MN). This concentration was based on previous reports of circulating serum BDNF levels of ~20 ng/ml which translates to <1 nM. To determine the role of TrkB, PASMCs were incubated in 1 μg/ml TrkB-Fc (Fc portion of TrkB receptor acting as extracellular BDNF neutralizing antibody, R & D Systems), ensuring adequate neutralization of nM concentrations of extracellular BDNF. The role of HIF1α was tested using an amidophenolic compound which blocks accumulation of HIF1α protein (preventing transcriptional activation) (#400083, EMD Millipore, 1 μM).

3. Immunofluorescence

Normoxia and hypoxia exposed human PASMCs were grown in serum free medium on 8 well slides with removable chambers. Medium was aspirated and cells were fixed in 2% paraformaldehyde for 15 min at room temperature, then washed 3 times in Tris buffered saline (TBS). Cells were then blocked with 5% donkey serum diluted in TBS for 1 h at room temperature on a shaker. Blocking solution was aspirated and primary antibody diluted 1:200 in TBS was added to appropriate wells. Control wells received no primary antibody. Primary antibody was incubated at 40°C overnight. Cells were then washed 3 times with TBS, and secondary antibody diluted 1:200 in TBS was added for 3 h at room temperature. Slides were finally washed, air dried, and coverslip mounted with DAPI Gelmount. Images were obtained using appropriate fluorescent wavelengths.

4. Serum/Extracellular BDNF Levels

Extracellular media from PA or PASMCs (see results) were processed for sandwich ELISA for BDNF (R&D Systems, Minneapolis, MN). Standard, manufacturer-provided protocols were used and colorimetric changes determined using a FlexStation3 microplate reader (Molecular Devices, Sunnyvale, CA) set to 450 nm (wavelength correction set to 540 nm) and compared to a standard, manufacturer-provided calibration curve.
5. Western Analysis

Standard SDS-PAGE (Criterion Gel System; Bio-Rad, Hercules, CA; 4–15% gradient gels) and PVDF membrane (Bio-Rad) transfer techniques were used. Membranes were blocked in buffer containing 5% powdered milk in TBS with 0.1% Tween-20 prior to addition of primary antibody (1 μg/mL rabbit anti-TrkB, Abcam, ab33655 or ab18987; rabbit anti-HIF1α, Novus Biologicals, #3376; rabbit anti-transgelin, Santa Cruz Biotechnology; sc-50446; mouse anti-β-actin, Abcam, AC-15). Markers of PASMC phenotype (smooth muscle actin, transgelin) were verified. As these PASMC markers, as well as β-actin, were relatively equally expressed in normoxic and hypoxic cells, we felt confident using β-actin expression as a measurable loading control. Protein detection and densitometry were done on Odyssey infrared imaging system (Li-Cor Biosciences) and all quantified bands were compared to the normoxia control band.

6. Real Time Calcium Imaging

We have previously published techniques for imaging of cellular [Ca2+]i.[38] Briefly, cells were incubated in 5 μM fluo-4-AM (Invitrogen) at room temperature for 45 min and fluorescence measurements made on a FlexStation3 microplate reader with micropipetting of 1 μM serotonin. Fluorescence was empirically calibrated in situ by exposing PASMCs to known Ca2+ levels with the ionophore A-23187.

7. Cell Proliferation Assay

Proliferation of PASMCs was assayed at 48h (with or without preceding interventions) using the fluorescent CyQuant NF kit (Invitrogen) as previously described.[19] Cells were exposed to CyQuant dye for 1h at room temperature, and measurements taken on the FlexStation3. Dye calibrations were performed empirically using different cell counts in order to obtain estimates of baseline proliferation and with interventions over 48h. Extent of proliferation was normalized to baseline (i.e. time zero).

8. Statistical Analysis

PA tissue or PASMC experiments were performed in samples from 3–7 patients (no pooling), with 3 repeats/sample. Data were analyzed and results were compared using one way ANOVA with Student-Newman-Keuls or Dunnet’s post hoc analysis using SigmaPlot (SYSTAT, San Jose, CA), and statistical significance was established at P < 0.05. Values are means ± SE.

Results

1. Hypoxia enhances PASMC-derived BDNF

Human PASMC were characterized by Western Blots demonstrating the presence of smooth muscle myosin, alpha smooth muscle actin, the acetylcholine receptor, and transgelin (Fig 1A). Western blot analysis of whole cell extracts of human PASMCs demonstrated the presence of BDNF with increased expression following hypoxia (Fig 1B, n = 3 patients without pulmonary vascular disease). In addition, immunohistochemistry demonstrated enhanced BDNF in hypoxia exposed PASMC compared to normoxia cells (Fig 1E). Importantly, ELISA of the supernatant from PASMCs exposed to normoxia vs. hypoxia (1% O2 which is known to induce HIF1α; see below)[8,39,40] demonstrated baseline presence of BDNF with increased secretion following hypoxia (Fig 1D; n = 7 patients without pulmonary vascular disease; p<0.05). In parallel Western blot studies, we found significantly increased full-length PASMC TrkB protein expression following hypoxia (Fig 1E; p<0.05). This increase in TrkB expression following hypoxia exposure further confirmed by immunofluorescence (Fig 1E).
2. Hypoxia enhances TrkB expression

Western blot analysis of endothelium-intact, normoxia vs. hypoxia-exposed PA segments (n = 5) from patients without pulmonary vascular disease, vs. normoxia-exposed PA segments from patients with moderate PH (Mean PAP clinically estimated by transthoracic or transesophageal echocardiography ranged from 25 mmHg (mild) to 48 mmHg (moderate)) (n = 3) showed that hypoxia as well as moderate PH resulted in increased TrkB expression, especially the full-length isoform (Fig 2A and 2B; representative blots of 2 samples from each group in (a), with average changes relative to normoxia in (b); p < 0.05). Similarly, enhanced BDNF expression (pro- and mature isoforms) was observed in PA samples exposed to hypoxia, and those with PH, although these changes in BDNF were not as pronounced as with TrkB (Fig 2C). On the other hand, BDNF ELISA of supernatant media from these tissue samples demonstrated significantly enhanced BDNF secretion following hypoxia (compared to normoxia controls), as well as enhanced baseline BDNF secretion in PA tissues from moderate PH patients albeit to a lesser extent compared to hypoxia effects (Fig 2D; p < 0.05).
Western blot analysis of PASMC lysates from PAs of patients without pulmonary vascular disease showed increased HIF1α protein expression following 48h of 1% hypoxia (Fig 3A; p<0.05). Importantly, in the presence of a HIF1α inhibitor, hypoxia-induced increase in TrkB protein expression was suppressed (Fig 3B; p<0.05). Consistent with TrkB activity relying on phosphorylation, Western analyses showed enhanced pTrkB following addition of BDNF at 30 and 60 min exposure times in normoxia, albeit not to the same extent as when PASMCs were exposed to hypoxia. Subsequent addition of exogenous BDNF at 30 and 60 min did not enhance pTrkB levels compared to hypoxia alone (Fig 3C).

### 3. BDNF/TrkB in hypoxia effects on \([\text{Ca}^{2+}]\) responses of PASMCs

Influo-4/AM loaded PASMCs of patients without pulmonary vascular disease, we found that 100 pM BDNF (in normoxia) enhanced the amplitude of \([\text{Ca}^{2+}]\), responses to 1 μM serotonin (5HT; Fig 4A; n = 5; p<0.05). In separate experiments, 5% hypoxia increased \([\text{Ca}^{2+}]\), responses to 5HT (Fig 4B; n = 5; p<0.05). Further addition of BDNF did not enhance responses to hypoxia. However, in the presence of the BDNF neutralizer, TrkB-Fc, hypoxia enhancement of \([\text{Ca}^{2+}]\), responses to 5HT was significantly blunted (p<0.05) but not eliminated. Furthermore, \([\text{Ca}^{2+}]\), responses to 5HT were diminished in the presence of the HIF1α inhibitor (Fig 4B; n = 5; p<0.05).
**BDNF, Hypoxia and Pulmonary Artery**

**a**

**Human PASMC**

| HIF-1α | Normoxia | Hypoxia |
|--------|----------|---------|
|        | 1        | 2       | 3       | 1       | 2       | 3       |
| Transgelin | ~120 kDa | 26 kDa  |
| β-actin    | 41 kDa    |         |

**HIF-1α Protein (AU)**

- Normoxia: 1
- Hypoxia: 8

* * *

**b**

**Human PASMC**

| HIF inh | Normoxia | Hypoxia |
|---------|----------|---------|
|        | -        | -       | -        | -        | +       | +       |
| TrkB FL | -        | +       | +        | -        | +       | +       |
| T1      | -        | -       | -        | -        | -       | -       |
| β-actin | 41 kDa    |         |

**TrkB Expression (AU)**

- Normoxia: -
- Hypoxia: *

* * *

**c**

**pTrkB**

- Normoxia: ~120 kDa
- Hypoxia: ~120 kDa

| β-actin | 41 kDa |
|---------|--------|

**BDNF (min)**

- 0, 30, 60

* * *
Fig 3. TrkB expression in PASMCs is enhanced by hypoxia. (a) In human PASMCs, 48h of 1% hypoxia enhanced expression of hypoxia-inducible factor (HIF-1α). Expression of β-actin or transgelin was not substantially altered showing maintenance of smooth muscle phenotype. (b) Hypoxia enhancement of TrkB was suppressed by pharmacological inhibition of HIF1α. Values are means ± SE (n = 7 patients). *Significant difference from normoxia, # significant effect of HIF-1α inhibition (p<0.05). (c) Western blot demonstrating phosphorylated TrkB expression in normoxia or hypoxia with exposure to BDNF for indicated times.

doi:10.1371/journal.pone.0129489.g003

Fig 4. BDNF in hypoxia enhancement of intracellular Ca2+ ([Ca2+]i) responses to agonist in human PASMCs. (a) Exposure of PASMCs to 1 μM serotonin (5HT; arrow) resulted in a transient [Ca2+]i response. Under normoxic conditions, 24h exposure to 100 pM BDNF enhanced the subsequent response to 1 μM 5HT, as reflected by increased amplitude (bar graph). (b) Hypoxia substantially enhanced [Ca2+]i responses of PASMCs to 5HT. Under conditions of hypoxia, BDNF did not produce any additional augmentation of these responses. However, neutralization of extracellular BDNF using the chimeric TrkB-Fc (1 μg/ml) protein blunted the effect of hypoxia. Similarly inhibition of HIF1α reduced the effect of hypoxia on the responses to 5HT. Values are means ± SE (n = 7 patients). *Significant difference from normoxia control, #significant effect of inhibitors from hypoxia control (p<0.05).

doi:10.1371/journal.pone.0129489.g004
4. BDNF/TrkB in hypoxia effects on survival pathways

Hypoxia has been previously shown to enhance PASMC survival and proliferation,[10,11,41] acting through pathways such as pPI3K and pAkt/Akt [25,42,43] which happen to overlap with BDNF signaling.[25] Representative Western blots are shown in Fig 5A and 5B. Following BDNF exposure in either normoxia or hypoxia, enhanced pPI3K and pERK until approximately 30 minutes of BDNF treatment were noted. No short term enhancement of pAkt was observed with BDNF. At 24h, however, (Fig 5B) enhanced phospho-protein expression was observed in the presence of BDNF, particularly pPI3K (Fig 5B) and pAkt (Fig 5C). Hypoxia alone also upregulated expression of these proteins. While the additional presence of BDNF did not further enhance pPI3K or pAkt/Akt levels in hypoxia, both the HIF1α inhibitor, and TrkB-Fc reduced expression of these pro-survival proteins in hypoxia exposed tissues (Fig 5B and 5C; n = 3 for each group; p<0.05 for BDNF, HIF1α inhibitor and TrkB-Fc).

In other cell systems, BDNF/TrkB signaling involves phosphorylation of ERK.[44,45] Western analysis of denuded PA tissue from patients (n = 3) without pulmonary vascular disease showed increased p-ERK/ERK protein levels in response to 24h BDNF exposure, comparable to that induced by hypoxia. Importantly, p-ERK/ERK levels were partially attenuated by the HIF1α inhibitor or by TrkB-Fc (Fig 5D; n = 3 for each group; p<0.05 for BDNF, HIF1α inhibitor and TrkB-Fc).

5. Role of BDNF in hypoxia effects on PASMC proliferation

An empirical calibration curve based on initially cell seeding concentrations and CyQuant fluorescence responsiveness [25] allowed comparisons of cell proliferation between groups. Serum-deprived PASMCs from patients without pulmonary vascular disease showed baseline proliferation of ~6% over a 48h period compared to time zero. Compared to baseline, PASMCs exposed to BDNF showed significantly greater proliferation (Fig 6A; p<0.05; n = 7 patients). Hypoxia alone also enhanced PASMC proliferation, and to a greater extent compared to BDNF only (p<0.05). The HIF1α inhibitor blunted hypoxia effects on proliferation. Furthermore, pre-treatment of hypoxia-exposed PASMC with TrkB-Fc also partially blunted PASMC proliferation (Fig 6A; p<0.05).

Fig 5. BDNF/TrkB in hypoxia effects on PASMC survival. Western blots for pPI3k, pAkt, and pERK in denuded human PA (aand b). After 24 hr hypoxia exposure, PI3 kinase (c) and pAkt/Akt (d) levels were both increased: effects blunted by BDNF neutralization or HIF1α inhibition. In normoxia, 100 pM BDNF enhanced PI3 kinase expression and Akt phosphorylation. 24h hypoxia also enhanced phosphorylation of ERK1/2 (e). In normoxia, 100 pM BDNF enhanced ERK1/2 phosphorylation. Extracellular neutralization of BDNF using TrkB-Fc (1 μg/ml) or inhibition of HIF1α blunted hypoxia effects on ERK phosphorylation. Values are means ± SE (n = 3 patients). *Significant difference from normoxia control; # significant inhibitor effect from hypoxia control (p<0.05).
Proliferation was further verified by Western blot analysis of PASMCs for proliferating cell nuclear antigen (PCNA) following exposure to BDNF or hypoxia, both of which showed increased PCNA (Fig 6B: \( p<0.05 \) compared to controls). The HIF1α inhibitor as well as TrkB-Fc in the presence of hypoxia each reduced PCNA levels.

6. BDNF does not appear to diminish apoptosis marker expression

Increased cell numbers can represent enhanced proliferation and/or reduced apoptosis. Fig 6C and 6D show that expression of anti-apoptosis markers MCL-1 and BCL-2 was not significantly enhanced by BDNF. However, there was a significant decrease in the expression of the apoptosis proteins caspase 3 and BAX (Fig 6C and 6E: \( p<0.05 \)). Hypoxia significantly enhanced anti-apoptosis protein markers, but decreased BAX (and not caspase 3). Consistently, a caspase 3/7 assay as a measure of apoptosis of PASMC exposed to normoxia vs. hypoxia (Fig 6F) showed no significant changes with BDNF or hypoxia.

Discussion

Responsiveness of PASMCs to hypoxia plays an important role in PA structure and function, making the effects of such insults on PA relevant to pathogenesis of diseases such as pulmonary hypertension. In the present study, we demonstrated a potential contribution of a the neurotrophin BDNF, which is not only released by PAECs [26] and PASMCs in response to hypoxia but can also have autocrine effects of enhancing \([\text{Ca}^{2+}]\), responses and cellular proliferation that occurs with hypoxia. As reported here and by others, BDNF can promote PASMC proliferation.[23] The relevance of BDNF to hypoxia is suggested by increased circulating levels in human serum exposed to hypoxia, as well as enhanced PAEC expression and secretion of BDNF as reported previously by us [26]. In addition, others have demonstrated enhanced BDNF mRNA expression in hypoxia-exposed lung and heart cells.[27] Furthermore, higher expression of BDNF in PAs of patients with PH suggests a potential role for this neurotrophin in this disease. Accordingly, our results contribute to previous data [23] that neurotrophins may have autocrine/paracrine effects that can mediate and modulate hypoxia effects on the PA.

Neurotrophins are a family of small growth factors that signal via high affinity Trk receptors.[14,15] However, there is increasing evidence that neurotrophins, particularly BDNF, as well as Trk and low affinity p75NTR receptors are widely distributed in non-neuronal, peripheral tissues including lung. [46] Immunocytochemical and other evidence suggest that BDNF and TrkB are expressed by the pulmonary vasculature.[23,46,47,48] In this regard, the intima and adventitia have been shown to have higher expression compared to smooth muscle.[22,47] In previous studies, we found that BDNF is expressed by human pulmonary endothelial cells [49] [26] and that PAEC BDNF expression and secretion is enhanced in hypoxia. [26] Furthermore, we had reported that both the ligand and the full-length TrkB receptor are expressed, suggesting a functional BDNF/TrkB system. The results of the present study now show that in addition to PA endothelial cells, human PASMCs also express BDNF and more importantly TrkB receptor, highlighting another, important local source as well as target of BDNF in the PA. More importantly, such expression is increased by hypoxia. Here, the higher expression of BDNF in the PAs of patients with moderate PH may be relevant given the importance of hypoxia in PH, although much work is still necessary to establish the functional relevance of elevated BDNF in PH, or the relationship between hypoxia, BDNF and PH pathogenesis/progression. Nonetheless, data from serum samples in healthy humans exposed to hypoxia is particularly relevant. [26] Previous studies have reported circulating neurotrophins, particularly BDNF (e.g.[50,51]), with increasing evidence for altered BDNF levels in response to
environmental and physiological stimuli.[52,53] In this regard, the serum BDNF levels observed in our study are comparable to other reports of ~20 ng/ml (which translates to <1 nM [35]; [54]; [37] justifying the use of a 100 pM concentration in our in vitro work).

While the present study, and our previous work [26] [22] highlight the presence of BDNF and its receptors in the PA, the functional relevance of BDNF/TrkB signaling warrants further investigation. We previously showed that BDNF works through TrkB to acutely (i.e. non-genomically) enhance endothelial NO production.[22] In other vascular beds, BDNF can increase eNOS expression and modulate endothelial cell proliferation, migration and survival via MAPK and PI3/Akt cascades.[55,56] These endothelium-based data would suggest that BDNF may facilitate vasodilation. However, it is currently unknown whether such a function is maintained in the setting of hypoxia or other factors such as inflammation. Our in vitro data showing that BDNF actually enhances [Ca²⁺], in PASMCs in the presence of hypoxia would suggest an opposing, vasoconstrictive effect that may offset any beneficial effects of BDNF on endothelium. Furthermore, the enhancing effect of BDNF on smooth muscle proliferation demonstrated in these data and reported by others [23] would only contribute to a thickened PA and increased contractility. In terms of [Ca²⁺⁺], regulation, BDNF can activate mechanisms such as IP₃ and influx pathways such as TRPCs, both of which are well-known to be important in PASMCs [8,57,58,59] and would contribute to increased contractility.

There are likely a number of mechanisms to explain how BDNF increases [Ca²⁺⁺], responses to serotonin, including enhancement of Ca²⁺ influx as well as enhanced SR Ca²⁺ release. Furthermore, the enhancing effect of BDNF on agonist responses is probably not specific only to serotonin. For example, we have previously demonstrated in human airway smooth cells that BDNF can increase baseline [Ca²⁺⁺], and responses to agonists such as Ach. [60] Further, with prolonged exposure, BDNF increases expression of a range of [Ca²⁺⁺], regulatory proteins such as CD38, Orai1, IP₃ and RyR receptors. [38] While BDNF did not affect baseline Ca²⁺⁺ in PASMCs, it is possible that prolonged BDNF exposure could indirectly increase [Ca²⁺⁺], by altering expression of regulatory proteins: a topic yet to be examined.

Separately, BDNF can promote an anti-apoptotic phenotype by enhancing MCL-1 [61] and BCL-2.[62] Hypoxia can induce anti-apoptotic proteins in PASMCs.[63] We found that BDNF tended to enhance expression of MCL-1 and BCL-2, and reduce caspase expression. These data support the idea that BDNF/TrkB signaling in human PASMC can contribute to hypoxia-induced effects in multiple ways.

Overall, these data point to a complex role of locally-produced BDNF within the PA that may detrimentally or beneficially influence arterial contractility and relaxation in a context-sensitive fashion. A single study in pulmonary artery rings from p75NTR knockout mice showed increased contractions to endothelin-1 [64] suggesting a vasodilatory role for neurotrophins, however such an effect cannot be attributed to BDNF (p75NTR is activated by all neurotrophins), to TrkB, or to PASMCs. Furthermore, it is likely that long-term lack of p75NTR could have a completely different effect on vascular structure and function.

Our studies show that hypoxia increases PASMC BDNF secretion resulting in autocrine effects, as demonstrated by neutralizing effects of the chimeric TrkB-Fc. Furthermore, hypoxia
increases TrkB receptor expression, facilitating autocrine BDNF effects, particularly in the setting of enhanced BDNF release. The mechanisms by which hypoxia enhances BDNF or TrkB expression are under investigation. While HIF1α would be an obvious choice, there are no HIF1α responsive elements on the BDNF gene. Whether hypoxia enhances BDNF secretion by other, indirect mechanisms including NFκB or MAPK is not known and warrants further investigation. On the other hand, there are at least three possible HIF1α response elements on the TrkB gene promoter, NTRK2.[34] In accordance, pharmacological inhibition of HIF1α reduced TrkB protein expression in PASMCs.

In terms of signaling, binding of BDNF results in TrkB autophosphorylation and triggering of a number of downstream enzymes and intracellular signaling cascades such as MAP kinases and PI3/Akt.[15,16] It is likely that the range of signaling mechanisms is both cell and context dependent. In human airway smooth muscle, we previously showed that MAPK, PI3/Akt and NFκB are all activated by BDNF, particularly with inflammation.[19] The present results showing activation of PI3/Akt and ERK are entirely consistent in this regard.

In conclusion, our study demonstrates enhancement of BDNF and TrkB expression and signaling in PASMCs following hypoxia, resulting in increased PASMC [Ca2+]i, and proliferation that can potentially contribute to hypoxia effects on arterial contractility and remodeling. While locally produced BDNF may be particularly important, the potential exists for circulating BDNF to further influence PA. Future studies should examine the mechanisms by which hypoxia can modulate endothelial vs. PASMC BDNF/TrkB signaling and the overall, in vivo effect on PA contractility and remodeling, especially in the context of diseases such as PH.

Acknowledgments
This work was supported by the Foundation of Anesthesia Education and Research (FAER) and an American Heart Association Grant in Aid (Hartman), the Flight Attendants Medical Research Institute (FAMRI; Sathish), the National Heart Lung and Blood Institute of the National Institutes of Health (R01 HL056470 and HL088029, Prakash), and the European Regional Development Fund-Project FNUSA-ICRC (No.CZ.1.05/1.1.00/02.0123) and ICRC Human Bridge—Support of Study Stays of Czech Researchers Abroad: "Young Talent Incubator" (reg. n. CZ.1.07/2.3.00/20.0022), which is financed by the European Social Fund and the state budget of the Czech Republic through The Education for Competitiveness Operational Program (Helan). Support for the human studies was from the National Science Foundation, B-179-M as well as funding through the Mayo Clinic Center for Translational Science (Johnson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Conceived and designed the experiments: WRH MH DS VS MT CMP BJ YSP. Performed the experiments: WRH MH DS. Analyzed the data: WRH MH DS VS MT CMP BJ YSP. Contributed reagents/materials/analysis tools: WRH CMP BJ YSP. Wrote the paper: WRH VS CMP YSP.

References
1. Frumkin LR (2012) The pharmacological treatment of pulmonary arterial hypertension. Pharmacological reviews 64: 583–620. doi: 10.1124/pr.111.005587 PMID: 22659328
2. Tajsic T, Morrell NW (2011) Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Comprehensive Physiology 1: 295–317. doi: 10.1002/cphy.c100026 PMID: 23737174
10. Sakao S, Tatsumi K, Voelkel NF (2010) Reversible or irreversible remodeling in pulmonary arterial hypertension. Journal of the American College of Cardiology 54: S20–31. doi: 10.1016/j.jacc.2009.04.018 PMID: 2055855

4. Kuhr FK, Smith KA, Song MY, Levitan I, Yuan JX (2012) New mechanisms of pulmonary arterial hypertension: role of Ca(2)(+) signaling. American journal of physiology Heart and circulatory physiology 302: H1546–1562. doi: 10.1152/ajpheart.00444.2011 PMID: 22245772

5. Stenmark KR, Raboinovitch M (2010) Emerging therapies for the treatment of pulmonary hypertension. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 11: S85–90.

6. McGlothlin D (2012) Classification of pulmonary hypertension. Heart failure clinics 8: 301–317. doi: 10.1016/j.hfc.2012.04.013 PMID: 22748896

7. McGoon MD, Miller DP (2012) REVEAL: a contemporary US pulmonary arterial hypertension registry. European respiratory review: an official journal of the European Respiratory Society 21: 8–18.

8. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, et al. (2006) Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca2+ in Pulmonary Arterial Smooth Muscle Cells. Circulation Research 98: 1528–1537. PMID: 16709899

9. Whitman EM, Pisarcik S, Luke T, Fallon M, Wang J, et al. (2008) Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. American Journal of Physiology—Lung Cellular and Molecular Physiology 294: L309–L318. PMID: 18065659

10. Sakao S, Tatsumi K, Voelkel NF (2010) Reversible or irreversible remodeling in pulmonary arterial hypertension. American journal of respiratory cell and molecular biology 43: 629–634. doi: 10.1165/rcmb.2009-0389TR PMID: 20008280

11. Pak O, Aldashev A, Welsh D, Peacock A (2007) The effects of hypoxia on the cells of the pulmonary vasculature. European Respiratory Journal 30: 364–372. PMID: 17665559

12. Davie NJ, Crossno JT, Frid MG, Hofmeister SE, Reeves JT, et al. (2004) Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. American Journal of Physiology—Lung Cellular and Molecular Physiology 286: L668–L678. PMID: 12754186

13. Rey S, Semenza GL (2010) Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovascular Research 86: 236–242. doi: 10.1093/cvr/cvq045 PMID: 20164116

14. Barbacid M (1995) Neurotrophic factors and their receptors. Curr Opin Cell Biol 7: 148–155. PMID: 7612265

15. Chao MV, Rajagopal R, Lee FS (2006) Neurotrophin signalling in health and disease. Clin Sci (Lond) 110: 167–173.

16. Ip NY, Yancopoulos GD (1994) Neurotrophic factors and their receptors. Ann Neurol 35 Suppl: S13–16. PMID: 8185289

17. Blum R, Konnerth A (2005) Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. Physiology (Bethesda) 20: 70–78.

18. Zhang J, Geula C, Lu C, Koziel H, Hatcher LM, et al. (2003) Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. Experimental Neurology 183: 469–481. PMID: 14552887

19. Aravamudan B, Thompson M, Pabelick C, Prakash YS (2012) Brain-derived neurotrophic factor induces proliferation of human airway smooth muscle cells. Journal of cellular and molecular medicine 16: 812–823. doi: 10.1111/j.1582-4934.2011.01356.x PMID: 21651720

20. Meuchel LW, Stewart A, Smelter DF, Abcejo AJ, Thompson MA, et al. (2011) Neurokinin-neurotrophin interactions in airway smooth muscle. American Journal of Physiology—Lung Cellular and Molecular Physiology 301: L91–L98. doi: 10.1152/ajplung.00320.2010 PMID: 21515660

21. Prakash YS, Iyanoye A, Ay B, Mantilla CB, Pabelick CM (2006) Neurotrophin effects on intracellular Ca2+ and force in airway smooth muscle. American journal of physiology Lung cellular and molecular physiology 291: L447–L456. PMID: 16648236

22. Meuchel LW, Thompson MA, Cassivi SD, Pabelick CM, Prakash YS (2011) Neurotrophins induce nitric oxide generation in human pulmonary artery endothelial cells. Cardiovascular research 91: 668–676. doi: 10.1093/cvr/cvr107 PMID: 21498417

23. Kwapiszewska G, Chwalek K, Marsh LM, Wygrecka M, Wilhelm J, et al. (2012) BDNF/TrkB Signaling Augments Smooth Muscle Cell Proliferation in Pulmonary Hypertension. The American Journal of Pathology 181: 2018–2029. doi: 10.1016/j.ajpath.2012.08.028 PMID: 23058367

24. Prakash YS, Iyanoye A, Ay B, Mantilla CB, Pabelick CM (2006) Neurotrophin effects on intracellular Ca2+ and force in airway smooth muscle. American Journal of Physiology—Lung Cellular and Molecular Physiology 291: L447–L456. PMID: 16648236
25. Aravamudan B, Thompson M, Pabelick C, Prakash YS (2012) Brain-derived neurotrophic factor induces proliferation of human airway smooth muscle cells. Journal of Cellular and Molecular Medicine 16: 812–823. doi: 10.1111/j.1582-4934.2011.01356.x PMID: 21651720

26. Helan M, Aravamudan B, Hartman WR, Thompson MA, Johnson BD, et al. (2014) BDNF secretion by human pulmonary artery endothelial cells in response to hypoxia. Journal of Molecular and Cellular Cardiology 68: 89–97. doi: 10.1016/j.yjmcc.2014.01.006 PMID: 24462831

27. Costello CM, Howell K, Cahill E, McBryan J, Konigshoff M, et al. (2008) Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. L272-L284 p.

28. Behrens MM, Strasser U, Lobner D, Dugan LL (1999) Neurotrophin-mediated potentiation of neuronal injury. Microscopy research and technique 45: 276–284. PMID: 10383120

29. Wang H, Yuan G, Prabhakar NR, Boswell M, Katz DM (2006) Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling. Journal of Neurochemistry 96: 694–705. PMID: 16390493

30. Behrens MM, Strasser U, Lobner D, Dugan LL (1999) Neurotrophin-mediated potentiation of neuronal injury. Microscopy research and technique 45: 276–284. PMID: 10383120

31. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo C-W, et al. (2006) Brain-Derived Neurotrophic Factor-1α in Neuroblastoma Cells. Cancer Research 66: 4249–4255. PMID: 16618748

32. Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, et al. (2012) Brain-Derived Neurotrophic Factor Protects Against Cardiac Dysfunction After Myocardial Infarction via a Central Nervous System–Mediated Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 1902–1909. doi: 10.1161/ATVBAHA.111.248930 PMID: 22556331

33. Pardridge WM (2002) Neurotrophins, neuroprotection and the blood-brain barrier. Current opinion in investigational drugs 3: 1753–1757. PMID: 12528312

34. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. American Journal of Physiology—Lung Cellular and Molecular Physiology 291: L941–L949. PMID: 16766575

35. Martens LK, Kirschner KM, Warnecke C, Scholz H (2007) Hypoxia-inducible Factor-1α Is a Transcriptional Activator of the TrkB Neurotrophin Receptor Gene. Journal of Biological Chemistry 282: 14379–14386. PMID: 17374610

36. Lommatsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, et al. (2005) The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiology of Aging 26: 115–123. PMID: 15585351

37. Bhang S-Y, Kim K, Choi S-W, Ahn J-H (2012) Do levels of brain-derived neurotrophic factor (BDNF) in plasma correlate with psychopathology in healthy subjects? Neuroscience Letters 512: 72–77. doi: 10.1016/j.neulet.2012.01.012 PMID: 22306615

38. Sciesielski LK, Paliege A, Martinka P, Scholz H (2009) Enhanced pulmonary expression of the TrkB neurotrophin receptor in hypoxic rats is associated with increased acetylcholine-induced airway contractility. Acta Physiologica 197: 253–264. doi: 10.1111/j.1748-1716.2009.02016.x PMID: 19583705

39. Martens LK, Kirschner KM, Warnecke C, Scholz H (2007) Hypoxia-inducible Factor-1 (HIF-1) Is a Transcriptional Activator of the TrkB Neurotrophin Receptor Gene. Journal of Biological Chemistry 282: 14379–14386. PMID: 17374610

40. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. American Journal of Physiology—Lung Cellular and Molecular Physiology 291: L941–L949. PMID: 16766575

41. Shimoda LA, Semenza GL (2011) HIF and the Lung. American Journal of Respiratory and Critical Care Medicine 183: 152–156. doi: 10.1164/rccm.201009-1393PP PMID: 21242594

42. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation research 99: 675–691. PMID: 17008597

43. Luo C, Yi B, Bai L, Xia Y, Wang G, et al. (2010) Suppression of Akt1 phosphorylation by adenoviral transfer of the PTEN gene inhibits hypoxia-induced proliferation of rat pulmonary arterial smooth muscle cells. Biochemical and Biophysical Research Communications 397: 486–492. doi: 10.1016/j.bbrc.2010.05.140 PMID: 20515660

44. Yi B, Cui J, Ning J-n, Wang G-s, Qian G-s, et al. (2012) Over-expression of PKGIα inhibits hypoxia-induced proliferation, Akt activation, and phenotype modulation of human PASMCs: The role of phenotype modulation of PASMCs in pulmonary vascular remodeling. Gene 492: 354–360. doi: 10.1016/j.gene.2011.11.010 PMID: 22101188
44. Slack SE, Grist J, Mac Q, McMahon SB, Pezet S (2005) TrkB expression and phospho-ERK activation by brain-derived neurotrophic factor in rat spinohthalamic tract neurons. The Journal of Comparative Neurology 489: 59–68. PMID: 15977164

45. Hetman M, Kanning K, Cavanaugh JE, Xia Z (1999) Neuroprotection by Brain-derived Neurotrophic Factor Is Mediated by Extracellular Signal-regulated Kinase and Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry 274: 22569–22580. PMID: 10428835

46. Prakash YS, Thompson MA, Meuchel CM, Mantilla CB, et al. (2010) Neurotrophins in lung health and disease. Expert Review of Respiratory Medicine 4: 395–411. doi: 10.1586/ers.10.29 PMID: 20524922

47. Ricci A, Greco S, Amenta F, Bronzetti E, Felici L, et al. (2000) Neurotrophins and neurotrophin receptors in human pulmonary arteries. Journal of vascular research 37: 355–363. PMID: 11025398

48. Ricci A, Felici L, Mariotta S, Mannino F, Schmid G, et al. (2004) Neurotrophin and Neurotrophin Receptor Protein Expression in the Human Lung. American Journal of Respiratory Cell and Molecular Biology 30: 12–19. PMID: 12791675

49. Meuchel LW, Stewart A, Smelter DF, Abejo AJ, Thompson MA, et al. (2011) Neurokinin-neurotrophin interactions in airway smooth muscle. American journal of physiology Lung cellular and molecular physiology 301: L91–98. doi: 10.1152/ajplung.00320.2010 PMID: 21515660

50. Araya AV, Orellana X, Godoy D, Soto L, Fiedler J (2013) Effect of Exercise on Circulating Levels of Brain-derived Neurotrophic Factor (BDNF) in Overweight and Obese Subjects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

51. Bejot Y, Mossiat C, Giroud M, Prigent-Tessier A, Marie C (2011) Circulating and brain BDNF levels in stroke rats. Relevance to clinical studies. PloS one 6: e29405. doi: 10.1371/journal.pone.0029405 PMID: 22195050

52. Grenli J, Bramham C, Murison R, Kanhma T, Fiske E, et al. (2006) Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. Pharmacology Biochemistry and Behavior 85: 842–849.

53. Cotman CW, Engesser-Cesar C (2002) Exercise Enhances and Protects Brain Function. Exercise and Sport Sciences Reviews 30: 75–79. PMID: 11991541

54. Cho HC, Kim J, Kim S, Son YH, Lee N, et al. (2012) The concentrations of serum, plasma and platelet BDNF are all increased by treadmill VO(2)max performance in healthy college men. Neuroscience letters 519: 78–83. doi: 10.1016/j.neulet.2012.05.025 PMID: 22617010

55. Kim H, Li Q, Hempstead BL, Madri JA (2004) Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. The Journal of biological chemistry 279: 33538–33546. PMID: 15169782

56. Caporali A, Emanuelli C (2009) Cardiovascular Actions of Neurotrophins. Physiological reviews 89: 279–308. doi: 10.1152/physrev.00007.2008 PMID: 19126759

57. Lu W, Wang J, Shimoda LA, Sylvester JT (2008) Differences in STIM1 and TRPC expression in proximal and distal pulmonary arterial smooth muscle are associated with differences in Ca2+ responses to hypoxia. American Journal of Physiology—Lung Cellular and Molecular Physiology 295: L104–L113. doi: 10.1152/ajplung.00058.2008 PMID: 18424621

58. Fuchs B, Dietrich A, Gudermann T, Kalwa H, Grimminger F, et al. (2010) The role of classical transient receptor potential channels in the regulation of hypoxic pulmonary vasoconstriction. Advances in experimental medicine and biology 661: 187–200. doi: 10.1007/978-1-60761-500-2_12 PMID: 20204731

59. Zhang W-M, Yip K-P, Lin M-J, Shimoda LA, Li W-H, et al. (2003) ET-1 activates Ca2+ sparks in PASMC: local Ca2+ signaling between inositol triphosphate and ryanodine receptors. American Journal of Physiology—Lung Cellular and Molecular Physiology 285: L680–L690. PMID: 12740215

60. Prakash YS, Thompson MA, Pabelick CM (2009) Brain-Derived Neurotrophic Factor in TNF-α Modulation of Ca2+ in Human Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology 41: 603–611. doi: 10.1165/rcmb.2008-0151OC PMID: 19213875

61. Cao X-I, Hu X-M, Hu J-Q, Zheng W-X (2011) Myocardin-related transcription factor-A promoting neuronal survival against apoptosis induced by hypoxia/ischemia. Brain Research 1385: 263–274. doi: 10.1016/j.brainres.2011.02.016 PMID: 21333636

62. Liu Z, Ma D, Feng G, Ma Y, Hu H (2007) Recombinant AAV-mediated expression of human BDNF protects neurons against cell apoptosis in Aβ-induced neuronal damage model. Journal of Huazhong University of Science and Technology—Medical Sciences—27: 233–236.

63. Archer SL, Gombert-Maitland M, Maitland ML, Rich S, Garcia JG, et al. (2008) Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the
intersection of pulmonary hypertension and cancer. American journal of physiology Heart and circulatory physiology. 294: H570–578. PMID: 18083891

64. Xu M, Remillard CV, Sachs BD, Makino A, Platsoshyn O, et al. (2008) p75 neurotrophin receptor regulates agonist-induced pulmonary vasoconstriction. Am J Physiol Heart Circ Physiol. 295: H1529–1538. doi: 10.1152/ajpheart.00115.2008 PMID: 18689502